Bain Capital Life Sciences Adjusts Stake in NewAmsterdam Pharma
Ticker: NAMSW · Form: SC 13D/A · Filed: Mar 1, 2024 · CIK: 1936258
Sentiment: neutral
Topics: amendment, ownership-change, pharma
TL;DR
Bain Capital Life Sciences filed an amendment to their 13D for NewAmsterdam Pharma. Ownership details updated.
AI Summary
Bain Capital Life Sciences Fund II, L.P. and its affiliates have amended their Schedule 13D filing regarding NewAmsterdam Pharma Co N.V. The filing, dated March 1, 2024, indicates a change in beneficial ownership. The group members include BAIN CAPITAL LIFE SCIENCES FUND II, L.P., BCIP LIFE SCIENCES ASSOCIATES, LP, and BCLS FUND III INVESTMENTS, LP.
Why It Matters
This amendment signals a potential shift in control or investment strategy by a significant institutional investor in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Amendments to Schedule 13D filings can indicate changes in a major shareholder's intentions, potentially impacting stock price and corporate strategy.
Key Players & Entities
- Bain Capital Life Sciences Fund II, L.P. (company) — Filing entity
- NewAmsterdam Pharma Co N.V. (company) — Subject company
- BCIP Life Sciences Associates, LP (company) — Affiliated entity
- BCLS Fund III Investments, LP (company) — Affiliated entity
FAQ
What specific change in beneficial ownership is reported in this amendment?
The filing is an amendment (Amendment No. 2) to a Schedule 13D, indicating a change in beneficial ownership, but the exact percentage or number of shares is not detailed in the provided text.
Who are the group members filing this amendment?
The group members are BAIN CAPITAL LIFE SCIENCES FUND II, L.P., BCIP LIFE SCIENCES ASSOCIATES, LP, and BCLS FUND III INVESTMENTS, LP.
What is the subject company's full name and CUSIP number?
The subject company is NewAmsterdam Pharma Company N.V., with a CUSIP number of N62509109.
When was this filing submitted and what is the date of the change?
The filing was submitted on March 1, 2024, and the date of the change is also listed as March 1, 2024.
What is the business address of the filing entity, BCLS II Investco, LP?
The business address for BCLS II Investco, LP is 200 Clarendon Street, Boston, MA 02116.
Filing Stats: 1,719 words · 7 min read · ~6 pages · Grade level 14.4 · Accepted 2024-03-01 16:30:31
Filing Documents
- d788549dsc13da.htm (SC 13D/A) — 78KB
- d788549dex99f.htm (EX-99.F) — 34KB
- 0001193125-24-056055.txt ( ) — 114KB
of the Initial Statement is hereby amended and supplemented to add the following
Item 6 of the Initial Statement is hereby amended and supplemented to add the following: February 2024 Lock-Up Agreement In connection with an underwritten public offering of the Ordinary Shares (the February 2024 Offering), the Reporting Persons and Dr. Downing each entered into a lock-up agreement (the February 2024 Lock-Up Agreement) with the representatives of the several underwriters of the February 2024 Offering, pursuant to which they each agreed, subject to certain exceptions, not to sell or offer to sell any Ordinary Shares or securities convertible into or exercisable or exchangeable for, Ordinary Shares for a period of 90 days after the date of the prospectus relating to the February 2024 Offering without the prior written consent of each of the representatives. CUSIP No. N62509109 13D Page 7 of 8 The foregoing summary of the February 2024 Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the February 2024 Lock-Up Agreement, which is filed as an exhibit hereto and incorporated by reference herein. Item7. Material to be filed as Exhibits
of
Item 7 of the Initial Statement is hereby amended and supplemented to add the following: Exhibit FForm of February 2024 Lock-Up Agreement CUSIP No. N62509109 13D Page 8 of 8
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: March 1, 2024 BCLS Fund III Investments, LP By: BCLS Fund III Investments GP, LLC, its general partner By: Bain Capital Life Sciences Fund III, L.P., its member By: Bain Capital Life Sciences III General Partner, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Name: Adam Koppel Title: Partner BCLS II Investco, LP By: BCLS II Investco (GP), LLC, its general partner By: Bain Capital Life Sciences Fund II, L.P., its managing member By: Bain Capital Life Sciences Investors II, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Name: Adam Koppel Title: Partner Bain Capital Life Sciences Fund II, L.P. By: Bain Capital Life Sciences Investors II, LLC, its general partner By: Bain Capital Life Sciences Investors, LLC, its manager By: /s/ Adam Koppel Name: Adam Koppel Title: Partner BCIP Life Sciences Associates, LP By: Boylston Coinvestors, LLC, its general partner By: /s/ Adam Koppel Name: Adam Koppel Title: Authorized Signatory